Insulin degludec

In plain language

Insulin degludec is an ultra-long basal insulin sold as Tresiba that lasts beyond 42 hours. It is combined with fast insulin in Ryzodeg and with the GLP-1 drug liraglutide in Xultophy.

Its trick is a fatty acid tag that makes insulin molecules link into long chains under the skin. These chains slowly dissolve apart, giving very steady insulin levels that do not depend on daily life. The flat profile means the daily dose can occasionally shift by a few hours without losing control.

For students

Insulin degludec links a 16-carbon fatty diacid to lysine B29 via a glutamic acid spacer, with threonine B30 removed. In the vial, phenol and zinc keep it as di-hexamers; after injection, the fatty chains interlock into large multi-hexamer strands that slowly shed monomers, giving a terminal half-life of roughly 25 hours and a duration beyond 42 hours.

Because of the resulting flat profile, the dosing interval can flex by up to 8 hours occasionally without loss of glycemic control. The FDA initially requested cardiovascular outcomes data before approval, a case study in 2008-era regulatory policy; the DEVOTE trial later demonstrated non-inferiority with less severe nocturnal hypoglycemia versus glargine.

For researchers and instructors

Biochemistry. The multi-hexamer formation is driven by fatty-acid interdigitation between adjacent hexamers, a reversible physical assembly distinct from chemical depot systems like glargine's precipitation.

Pharmacology. Ultra-flat exposure with fourfold lower day-to-day variability than glargine U100 in clamp studies; flexible dosing window is a labeled feature.

Human evidence. BEGIN program registration trials, DEVOTE (7,637 patients) showing less severe and nocturnal hypoglycemia, and SWITCH trials in type 1 and type 2 diabetes.

Teaching point. Demonstrates the regulatory shift to requiring cardiovascular outcomes trials for diabetes drugs, and how pharmacokinetic flatness translates into clinical flexibility.